Literature DB >> 27098364

(18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma.

Chaitra S Ujjani1, Elizabeth M Hill1, Hongkun Wang2, Samer Nassif3, Giuseppe Esposito4, Metin Ozdemirli3, Christine Cordova1, Bruce D Cheson1.   

Abstract

The ability of positron emission tomography-computerized tomography (PET-CT) to accurately detect bone marrow involvement (BMI) has been suggested in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL), but its abilities in other histologies is less established. The aim of this retrospective study was to confirm the role of PET-CT in detecting BMI in DLBCL and HL, and to explore its usefulness in other subtypes. Of the 149 newly diagnosed patients, common subtypes included DLBCL, follicular lymphoma (FL) and HL. In DLBCL, the sensitivity and specificity of PET-CT at diagnosis were 75% and 92%. In FL, the sensitivity and specificity of PET-CT were 67% and 85% at diagnosis, and 73% and 89% at relapse. In HL, the sensitivity and specificity were 100% and 74%. PET-CT was able to detect BMI in patients with negative biopsies. Most of the patients in which PET-CT failed to identify BMI were already advanced stage by imaging. In this analysis, PET-CT was highly accurate for detecting BMI at diagnosis in DLBCL and HL and highly specific in FL at diagnosis and relapse. Results also suggested the diagnostic advantage of PET-CT over bone marrow biopsy in detecting BMI. Prospective evaluation is necessary and may eliminate biopsies in future patients.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  bone marrow biopsy; lymphoma; positron emission tomography-computerized tomography; stage

Mesh:

Substances:

Year:  2016        PMID: 27098364     DOI: 10.1111/bjh.14071

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information.

Authors:  Reiko Nakajima; Alison J Moskowitz; Laure Michaud; Audrey Mauguen; Connie Lee Batlevi; Ahmet Dogan; Heiko Schöder
Journal:  Blood Adv       Date:  2020-04-28

2.  Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.

Authors:  Frédérique St-Pierre; Stephen M Broski; Betsy R LaPlant; Matthew J Maurer; Kay Ristow; Gita Thanarajasingam; William R Macon; Thomas M Habermann; Thomas E Witzig
Journal:  Oncologist       Date:  2020-04-28

3.  Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA.

Authors:  Sarah C Rutherford; Michael Herold; Wolfgang Hiddemann; Lale Kostakoglu; Robert Marcus; Maurizio Martelli; Laurie H Sehn; Marek Trněný; Judith Trotman; Umberto Vitolo; Tina Nielsen; Federico Mattiello; Deniz Sahin; Gila Sellam; Peter Martin
Journal:  Blood Adv       Date:  2020-04-28

4.  PET/CT predicts bone marrow involvement in paediatric non-Hodgkin lymphoma and may preclude the need for bone marrow biopsy in selected patients.

Authors:  Suyun Chen; Shaoyan Wang; Kejun He; Chao Ma; Hongliang Fu; Hui Wang
Journal:  Eur Radiol       Date:  2018-01-30       Impact factor: 5.315

5.  Utility of 18F-fluorodeoxyglucose PET-CT scan in detecting bone marrow involvement in lymphoma.

Authors:  Ankit Kumar Jitani; Shyamali Dutta; Prakas Kumar Mandal; Rajib De; Ekta Jajodia; Shuvraneel Baul; Prantar Chakrabarti; Tuphan Kanti Dolai
Journal:  Indian J Med Res       Date:  2021-05       Impact factor: 5.274

Review 6.  Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions.

Authors:  Huan Chen; Tao Pan; Yizi He; Ruolan Zeng; Yajun Li; Liming Yi; Hui Zang; Siwei Chen; Qintong Duan; Ling Xiao; Hui Zhou
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

7.  Diagnostic value of baseline 18FDG PET/CT skeletal textural features in follicular lymphoma.

Authors:  Julie Faudemer; Nicolas Aide; Anne-Claire Gac; Ghandi Damaj; Jean-Pierre Vilque; Charline Lasnon
Journal:  Sci Rep       Date:  2021-12-10       Impact factor: 4.379

8.  Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.

Authors:  Tzu-Hua Chen-Liang; Taida Martín-Santos; Andrés Jerez; Guillermo Rodríguez-García; Leonor Senent; Cristina Martínez-Millán; Begoña Muiña; Mayte Orero; Anabel Teruel; Alejandro Martín; Joaquín Gómez-Espuch; Kyra Kennedy; Carmen Benet; José María Raya; Marta Fernández-González; Fátima de la Cruz; Marta Guinot; Carolina Villegas; Isabel Ballester; Mónica Baile; María Moya; Javier López-Jiménez; Laura Frutos; José Luis Navarro; Jon Uña; Rosa Fernández-López; Carolina Igua; José Contreras; Raquel Sánchez-Vañó; María Del Puig Cozar; Pilar Tamayo; Jorge Mucientes; José Javier Sánchez-Blanco; Elena Pérez-Ceballos; Francisco José Ortuño
Journal:  Cancer Med       Date:  2017-09-27       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.